RYTM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RY

Mkt Cap

$5.94B

Volume

267.97K

Next Earnings

November 3rd

Loading chart

RY

RYTMRhythm Pharmaceuticals, Inc. Common Stock

RYTM

Pay with—

Available Balance0.00

RY

Mkt Cap

$6.06B

Volume

267.97K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan following MHLW approval and inclusion on Japan's National Health Insurance drug price list. IMCIVREE is the first approved therapy in Japan for acquired hypothalamic obesity, with an estimated patient population of 5,000-8,000 people. The approval was supported by Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction.GlobeNewswire Inc. · Oct 13, 2026

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should KnowRhythm Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months (up 8.5%). The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and institutional investor buying pressure.Zacks Investment Research · Oct 13, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic ObesityRhythm Pharmaceuticals announced preliminary Phase 2 trial results for RM-718, an investigational MC4R agonist, showing an 11.6% mean BMI reduction in acquired hypothalamic obesity patients at 16 weeks. The efficacy is comparable to existing treatments setmelanotide and bivamelagon, with notably reduced hyperpigmentation side effects (only 2 mild injection site cases). The company will discuss Q2 2026 financial results in a conference call.GlobeNewswire Inc. · Aug 4, 2026

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.GlobeNewswire Inc. · Jul 17, 2026

Why Is Rhythm Pharma Stock Jumping Today?Rhythm Pharmaceuticals (NASDAQ: RYTM) stock surged 5.47% after presenting six-month Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients. The study showed meaningful improvements in BMI (3.06% mean reduction), body composition, hyperphagia, and behavioral measures, with a consistent safety profile. The trial enrolled 18 patients aged 6-23, with 17 remaining on active treatment.Benzinga · Jun 15, 2026

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026Rhythm Pharmaceuticals announced that seven presentations, including four late-breaking abstracts, have been accepted for The Endocrine Society's Annual Meeting (ENDO 2026) in Chicago from June 13-16, 2026. The presentations will showcase clinical trial data for setmelanotide and bivamelagon in treating rare neuroendocrine diseases including Prader-Willi syndrome, acquired hypothalamic obesity, and Bardet-Biedl syndrome. The company will also host its inaugural MOMENTUM meeting on June 12 to discuss advances in MC4R pathway diseases.GlobeNewswire Inc. · May 29, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesRhythm Pharmaceuticals announced that its Chairman, President and CEO David Meeker and CFO Hunter Smith will participate in fireside chats at the Jefferies Global Healthcare Conference (June 4, 2026) and Goldman Sachs 47th Annual Global Healthcare Conference (June 8, 2026), respectively. The company's lead asset IMCIVREE (setmelanotide) is an FDA-approved MC4R agonist for treating rare obesity conditions including acquired hypothalamic obesity and genetic syndromes like Bardet-Biedl syndrome.GlobeNewswire Inc. · May 26, 2026

Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors.Green Thumb Industries has filed for DEA registration following the rescheduling of marijuana to Schedule III, positioning itself as a first-mover in the evolving U.S. cannabis landscape. The move could attract institutional investors, enable research partnerships, and potentially lead to major stock exchange listings if recreational cannabis is also rescheduled. CEO Ben Kovler emphasized that this strategic action normalizes the federal cannabis industry.The Motley Fool · May 14, 2026

Rhythm Pharmaceuticals Announces Changes to Board of DirectorsRhythm Pharmaceuticals announced the appointment of Kim Popovits, an accomplished life sciences leader with 40+ years of experience, to its Board of Directors, replacing departing board member Ed Mathers who served since 2013. Popovits brings extensive expertise in commercialization, reimbursement, and governance from her previous roles at Genomic Health and Genentech.GlobeNewswire Inc. · Apr 3, 2026

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic ObesityRhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity, becoming the first and only FDA-approved therapy for this rare disease. The approval is based on Phase 3 TRANSCEND trial results showing an 18.4% placebo-adjusted BMI reduction in 142 patients. The drug is indicated for adults and pediatric patients aged 4 years and older.GlobeNewswire Inc. · Mar 19, 2026

to start trading

RY

RYTMRhythm Pharmaceuticals, Inc. Common Stock

RYTM

Pay with—

Available Balance0.00

Your PositionYou don't own any RYTM yet.

Related Tickers

Earnings